stockrow
Saturday 7 November 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023.
- Revenue
- +147.7%
- EPS
- +98.4%
- Free cash flow
- −45.0%
Quarter to June 2026, against a year earlier
1.61
0.04
−2.42%
Follow ELAB
Alert me
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | — | 0.00 |
Altman Z-Score |
— | 7.22 | — | (3.65) |
P/S ratio |
27,712,441.26 | 0.00 | — | 0.79 |
P/FCF ratio |
0.00 | 0.00 | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
(6.15) | 1.64 | — | (5.79) |
P/Operating CF |
(77,906,223.37) | 0.00 | — | (0.77) |
Beneish M-Score |
— | 0.18 | — | — |
P/B ratio |
0.00 | 0.00 | — | 0.17 |
Price to Tangible BV |
0.00 | 0.00 | — | 0.34 |
EV/Sales |
27,712,440.93 | (1.94) | — | (2.63) |
EV/EBITDA |
0.00 | 28.85 | — | 0.67 |
EV/Operating CF |
(14,980,173.75) | 0.73 | — | 0.76 |
EV/FCF |
(14,925,497.51) | 0.73 | — | 0.71 |
Quick Ratio |
1.99 | 2.57 | 2.22 | 1.60 |
Current Ratio |
2.64 | 3.79 | 3.36 | 1.74 |
Net Debt/EBITDA |
0.65 | 2.95 | 0.95 | 0.87 |
Debt/Assets |
0.00% | 0.00% | 5.94% | 0.66% |
Debt/Equity |
0.00 | 0.00 | 0.08 | 0.01 |
Asset Turnover |
0.00 | 0.48 | 0.00 | 0.05 |
Operating CF/Net income |
0.88 | 1.06 | 0.88 | 0.77 |
Capex/Depreciation |
(4.92) | (0.97) | (36.27) | (4.64) |
Interest Coverage |
(688.85) | (58.51) | (4.98) | (26.72) |
| 0.00% | (173.52%) | (119.12%) | (106.89%) | |
| 0.00% | (121.48%) | (88.07%) | (70.88%) | |
ROIC |
0.00% | (142.57%) | (71.34%) | (220.80%) |
Return on Tangible Assets |
(177.11%) | (118.70%) | (146.85%) | (203.11%) |
Average Days of Receivables |
6.14 | 0.66 | 0.00 | 210.61 |
Research and Development Expense of Revenue |
29.84% | 0.43% | 0.00% | 24.91% |
Selling, General and Administrative Expense of Revenue |
158.24% | 35.27% | 0.00% | 413.42% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.31 | 0.30 |
Share Based Compensation of Revenue |
22.43% | 28.48% | 0.00% | (3.25%) |
Graham Net Nets |
0.00 | 0.00 | — | 1.36 |
Graham Number |
0.00 | 0.00 | — | 0.00 |
Earnings Yield |
0.00% | (4.22%) | — | (1,356.08%) |
Free Cash Flow Yield |
0.00% | 0.00% | — | (471.64%) |
Revenue per Share |
0.08 | 187,421.34 | 0.00 | 289.95 |
Operating CF per Share |
(0.17) | (498,681.29) | (57,940.87) | (2,915.63) |
Capex per Share |
0.00 | (1,225.69) | (4,978.88) | (220.27) |
Free Cash Flow per Share |
(0.17) | (499,906.98) | (62,919.75) | (3,135.91) |
Cash per Share |
0.12 | 364,085.05 | 42,074.97 | 2,935.53 |
Shareholders Equity per Share |
0.12 | 418,825.31 | 70,323.13 | 3,850.92 |
Interest Debt per Share |
0.00 | 0.00 | 0.01 | 0.00 |
Book value per Share |
0.12 | 418,825.31 | 70,323.13 | 3,850.92 |
Free Cash Flow |
(1.62) | (4.57) | (5.96) | (6.38) |
Working Capital |
0.96 | 3.62 | 4.25 | 2.93 |
Capital Expenditures |
(0.03) | (0.01) | (0.47) | (0.45) |
Net Current Asset Value |
0.79 | 3.56 | 3.72 | 1.84 |
EV/EBIT |
0.00 | 2.92 | — | 0.66 |
Capex to Sales |
0.04 | 0.01 | 0.00 | 0.76 |
Price to Operating Income |
0.00 | 0.00 | — | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.12 | 6.82 | 11.82 | 0.11 |
Cash ROIC |
(70.77%) | (63.85%) | (53.30%) | (45.93%) |
Accounts Receivable Turnover |
0.00 | 214.08 | 0.00 | 3.41 |
Accounts Payable Turnover |
0.00 | 3.05 | 0.00 | 0.69 |
Inventory Turnover |
0.00 | 1.59 | — | 1.37 |
Average Days of Payables |
279.99 | 84.62 | 0.00 | 629.01 |
Days of Inventory on Hand |
263.28 | 313.03 | — | 85.75 |
Average Receivables |
— | 0.01 | 0.00 | 0.17 |
Average Payables |
— | 0.19 | 0.31 | 0.59 |
Average Inventory |
— | 0.36 | — | 0.30 |
Average Assets |
— | 3.54 | 7.09 | 10.93 |
Average Common Equity |
— | 2.48 | 5.24 | 7.25 |
Columns are period end dates · fundamentals updated 26 Oct 2026